Ivonescimab Plus Chemotherapy Approved for First-Line Squamous NSCLC; HARMONi-6 Establishes New Gold Standard in Lung Cancer Treatment
HONG KONG, Aug. 12, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the China National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for ivonescimab injection in combination with chemotherapy for...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.